451
|
Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98:1183-92. [PMID: 16954471 DOI: 10.1093/jnci/djj329] [Citation(s) in RCA: 814] [Impact Index Per Article: 45.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND A 70-gene signature was previously shown to have prognostic value in patients with node-negative breast cancer. Our goal was to validate the signature in an independent group of patients. METHODS Patients (n = 307, with 137 events after a median follow-up of 13.6 years) from five European centers were divided into high- and low-risk groups based on the gene signature classification and on clinical risk classifications. Patients were assigned to the gene signature low-risk group if their 5-year distant metastasis-free survival probability as estimated by the gene signature was greater than 90%. Patients were assigned to the clinicopathologic low-risk group if their 10-year survival probability, as estimated by Adjuvant! software, was greater than 88% (for estrogen receptor [ER]-positive patients) or 92% (for ER-negative patients). Hazard ratios (HRs) were estimated to compare time to distant metastases, disease-free survival, and overall survival in high- versus low-risk groups. RESULTS The 70-gene signature outperformed the clinicopathologic risk assessment in predicting all endpoints. For time to distant metastases, the gene signature yielded HR = 2.32 (95% confidence interval [CI] = 1.35 to 4.00) without adjustment for clinical risk and hazard ratios ranging from 2.13 to 2.15 after adjustment for various estimates of clinical risk; clinicopathologic risk using Adjuvant! software yielded an unadjusted HR = 1.68 (95% CI = 0.92 to 3.07). For overall survival, the gene signature yielded an unadjusted HR = 2.79 (95% CI = 1.60 to 4.87) and adjusted hazard ratios ranging from 2.63 to 2.89; clinicopathologic risk yielded an unadjusted HR = 1.67 (95% CI = 0.93 to 2.98). For patients in the gene signature high-risk group, 10-year overall survival was 0.69 for patients in both the low- and high-clinical risk groups; for patients in the gene signature low-risk group, the 10-year survival rates were 0.88 and 0.89, respectively. CONCLUSIONS The 70-gene signature adds independent prognostic information to clinicopathologic risk assessment for patients with early breast cancer.
Collapse
Affiliation(s)
- Marc Buyse
- International Drug Development Institute, Brussels, Belgium
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
452
|
Abstract
We recently identified a gene expression cassette of 97 unique genes that were consistently differentially expressed between low and high grade breast carcinomas. The majority of these genes were overexpressed in high grade tumors and, as expected, they were associated with cell cycle progression and proliferation. Interestingly, by applying this gene expression cassette to several datasets, we demonstrated that intermediate grade tumors were composed of a mixture of well- and poorly- differentiated tumors with statistically distinct clinical outcome similar to those of low and high grade carcinomas. Furthermore, these proliferation-related genes appear to be a common denominator of several existing prognostic gene expression signatures. This recapitulates their prognostic power far beyond the estrogen receptor (ER) status and highlights the importance of proliferation genes in breast cancer biology. Importantly, their weight seems to be far more important in ER-positive than in ER-negative disease.
Collapse
Affiliation(s)
- Christine Desmedt
- Functional Genomics and Translational Research Unit, Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
| | | |
Collapse
|
453
|
Lothaire P, de Azambuja E, Dequanter D, Lalami Y, Sotiriou C, Andry G, Castro G, Awada A. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 2006; 28:256-69. [PMID: 16284973 DOI: 10.1002/hed.20326] [Citation(s) in RCA: 113] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
BACKGROUND The aim of this article is to review recent developments in the biological understanding of head and neck squamous cell carcinomas. METHODS AND RESULTS We describe the markers according to their function and their prognostic or predictive roles. Some associations can be found between molecular markers and invasiveness, aggressiveness, degree of differentiation, and tumor stage, but only a few clinical studies have shown an impact on prognosis. In addition, despite an increasing number of articles relating to this topic, the small number of patients included in the studies reported reduces the clinical implications of these results. Few studies applied a more comprehensive molecular analysis approach, such as DNA microarrays or differential expression profiling by polymerase chain reaction, to identify a combination of markers that could be more informative than a single molecular marker. CONCLUSION Some progress has been made with respect to molecular markers and head and neck cancers. Translational and prospective, hypothesis-driven research must proceed with sufficient rigor to facilitate the clinical applicability of such results.
Collapse
|
454
|
Bernard-Marty C, Cardoso F, Sotiriou C, Piccart MJ. [Towards an individualization of systemic treatment of breast tumors]. Bull Cancer 2006; 93:791-7. [PMID: 16935784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Clinical trials of adjuvant treatment of breast cancers have been limited for a long time to overall comparisons of heterogeneous populations. A new generation of clinical trials should be implemented, with especially the selection of the patients as a function of the molecular characteristics of their tumour. Unquestionable biological data must be taken into account to raise relevant questions, such as the role of topoisomerase II in the response to anthracyclines or the role of p53 in the response to taxanes. Microarrays technology, which allows the establishment of expression profiles of the whole genome, are very powerful tools which have allowed to reclassify breast tumours and to obtain "molecular signatures" characteristic for the risk of metastatic recurrence. A large randomised prospective study has been recently initiated with the aim of comparing the prognostic value of this signature to that of classical histopathologic criteria. In the next future, it will be possible to consider an individualisation of the prescription of cancer chemotherapies on molecular validated bases.
Collapse
Affiliation(s)
- C Bernard-Marty
- Département de médecine, Institut Jules-Bordet, Bruxelles, Belgique
| | | | | | | |
Collapse
|
455
|
Sotiriou C, Wirapati P, Loi S, Haibe-Kains B, Desmedt C, Tutt A, Ellis P, Buyse M, Delorenzi M, Piccart M. Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1,500 samples: Proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer (BC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.507] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
507 Background: Although, the development of high-throughput gene expression technologies has allowed the identification of several “molecular signatures” predicting clinical outcome, no attempt has been made yet to perform a comprehensive analysis integrating both clinicopathological, and gene expression data. Here, we aim to elucidate the relationship between clinical parameters and tumor markers, with gene expression patterns and their interaction with prognosis. Methods: We analyzed gene expression and clinical data from several published studies, including more than 1500 BC patients. We developed several gene expression indices associated with different biological stages of disease characterized by the expression of hormone receptors, HER2 amplification, p53 mutation, angiogenesis, tumor invasion and proliferation. Multivariable analyses were used to characterize the dependency patterns between these indices and their impact on survival. Results: Estrogen receptor (ER) and HER2 indices were the most prominent discriminators dichotomizing tumor samples into two main subsets in agreement with the previously proposed BC subtypes. Tumor proliferation, assessed by our previously reported gene expression index (GGI), was the most strongly associated with prognosis (HR 2.29, CI 1.88–2.78, p<0.0001). Almost all ER- and HER2+ tumors were associated with high GGI scores. In contrast, ER+ and HER2- tumors showed a whole range of GGI values. Within the high proliferation subset, ER- and HER2+ indices did not have any prognostic value. Similar results were found with relation to p53 mutation index. Nodal status and tumor size, which essentially measure the duration of disease, retained prognostic value in addition to proliferation. Conclusions: Proliferation captured by the GGI appears to be a key biological factor, downstream of ER, HER2 and p53. Although understanding the upstream factors is important for advancing biological knowledge and therapeutic interventions, GGI seems to be the most important factor predicting clinical outcome in BC and deserves consideration as stratification factor in clinical trials. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Sotiriou
- Jules Bordet Institute, Brussels, Belgium; Swiss Institute of Experimental Cancer Research, Epalinges, Switzerland; Peter MacCallum Cancer Center, Melbourne, Australia; Guy’s Hospital, London, United Kingdom; IDDI, Brussels, Belgium
| | - P. Wirapati
- Jules Bordet Institute, Brussels, Belgium; Swiss Institute of Experimental Cancer Research, Epalinges, Switzerland; Peter MacCallum Cancer Center, Melbourne, Australia; Guy’s Hospital, London, United Kingdom; IDDI, Brussels, Belgium
| | - S. Loi
- Jules Bordet Institute, Brussels, Belgium; Swiss Institute of Experimental Cancer Research, Epalinges, Switzerland; Peter MacCallum Cancer Center, Melbourne, Australia; Guy’s Hospital, London, United Kingdom; IDDI, Brussels, Belgium
| | - B. Haibe-Kains
- Jules Bordet Institute, Brussels, Belgium; Swiss Institute of Experimental Cancer Research, Epalinges, Switzerland; Peter MacCallum Cancer Center, Melbourne, Australia; Guy’s Hospital, London, United Kingdom; IDDI, Brussels, Belgium
| | - C. Desmedt
- Jules Bordet Institute, Brussels, Belgium; Swiss Institute of Experimental Cancer Research, Epalinges, Switzerland; Peter MacCallum Cancer Center, Melbourne, Australia; Guy’s Hospital, London, United Kingdom; IDDI, Brussels, Belgium
| | - A. Tutt
- Jules Bordet Institute, Brussels, Belgium; Swiss Institute of Experimental Cancer Research, Epalinges, Switzerland; Peter MacCallum Cancer Center, Melbourne, Australia; Guy’s Hospital, London, United Kingdom; IDDI, Brussels, Belgium
| | - P. Ellis
- Jules Bordet Institute, Brussels, Belgium; Swiss Institute of Experimental Cancer Research, Epalinges, Switzerland; Peter MacCallum Cancer Center, Melbourne, Australia; Guy’s Hospital, London, United Kingdom; IDDI, Brussels, Belgium
| | - M. Buyse
- Jules Bordet Institute, Brussels, Belgium; Swiss Institute of Experimental Cancer Research, Epalinges, Switzerland; Peter MacCallum Cancer Center, Melbourne, Australia; Guy’s Hospital, London, United Kingdom; IDDI, Brussels, Belgium
| | - M. Delorenzi
- Jules Bordet Institute, Brussels, Belgium; Swiss Institute of Experimental Cancer Research, Epalinges, Switzerland; Peter MacCallum Cancer Center, Melbourne, Australia; Guy’s Hospital, London, United Kingdom; IDDI, Brussels, Belgium
| | - M. Piccart
- Jules Bordet Institute, Brussels, Belgium; Swiss Institute of Experimental Cancer Research, Epalinges, Switzerland; Peter MacCallum Cancer Center, Melbourne, Australia; Guy’s Hospital, London, United Kingdom; IDDI, Brussels, Belgium
| |
Collapse
|
456
|
|
457
|
Azambuja E, Castro G, Durbecq V, Paesmans M, Ismael G, Larsimont D, Sotiriou C, Piccart M, Cardoso F. The triple negative profile dilemma and its clinical outcome in early breast cancer. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)80313-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
458
|
Sotiriou C, Wirapati P, Loi S, Desmedt C, Haibe-Kains B, Piette F, Buyse M, Bontempi G, Delorenzi M, Piccart M. Is genomic grading killing histological grading? EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)80452-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
459
|
Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98:262-72. [PMID: 16478745 DOI: 10.1093/jnci/djj052] [Citation(s) in RCA: 1461] [Impact Index Per Article: 81.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Histologic grade in breast cancer provides clinically important prognostic information. However, 30%-60% of tumors are classified as histologic grade 2. This grade is associated with an intermediate risk of recurrence and is thus not informative for clinical decision making. We examined whether histologic grade was associated with gene expression profiles of breast cancers and whether such profiles could be used to improve histologic grading. METHODS We analyzed microarray data from 189 invasive breast carcinomas and from three published gene expression datasets from breast carcinomas. We identified differentially expressed genes in a training set of 64 estrogen receptor (ER)-positive tumor samples by comparing expression profiles between histologic grade 3 tumors and histologic grade 1 tumors and used the expression of these genes to define the gene expression grade index. Data from 597 independent tumors were used to evaluate the association between relapse-free survival and the gene expression grade index in a Kaplan-Meier analysis. All statistical tests were two-sided. RESULTS We identified 97 genes in our training set that were associated with histologic grade; most of these genes were involved in cell cycle regulation and proliferation. In validation datasets, the gene expression grade index was strongly associated with histologic grade 1 and 3 status; however, among histologic grade 2 tumors, the index spanned the values for histologic grade 1-3 tumors. Among patients with histologic grade 2 tumors, a high gene expression grade index was associated with a higher risk of recurrence than a low gene expression grade index (hazard ratio = 3.61, 95% confidence interval = 2.25 to 5.78; P < .001, log-rank test). CONCLUSIONS Gene expression grade index appeared to reclassify patients with histologic grade 2 tumors into two groups with high versus low risks of recurrence. This approach may improve the accuracy of tumor grading and thus its prognostic value.
Collapse
Affiliation(s)
- Christos Sotiriou
- Functional Genomics and Translational Research Unit, Université Libre de Bruxelles, Brussels, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
460
|
Klener P, Szynal M, Cleuter Y, Merimi M, Duvillier H, Lallemand F, Bagnis C, Griebel P, Sotiriou C, Burny A, Martiat P, Van den Broeke A. Insights into gene expression changes impacting B-cell transformation: cross-species microarray analysis of bovine leukemia virus tax-responsive genes in ovine B cells. J Virol 2006; 80:1922-38. [PMID: 16439548 PMCID: PMC1367148 DOI: 10.1128/jvi.80.4.1922-1938.2006] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Large-animal models for leukemia have the potential to aid in the understanding of networks that contribute to oncogenesis. Infection of cattle and sheep with bovine leukemia virus (BLV), a complex retrovirus related to human T-cell leukemia virus type 1 (HTLV-1), is associated with the development of B-cell leukemia. Whereas the natural disease in cattle is characterized by a low tumor incidence, experimental infection of sheep leads to overt leukemia in the majority of infected animals, providing a model for studying the pathogenesis associated with BLV and HTLV-1. Tax(BLV), the major oncoprotein, initiates a cascade of events leading toward malignancy, although the basis of transformation is not fully understood. We have taken a cross-species ovine-to-human microarray approach to identify Tax(BLV)-responsive transcriptional changes in two sets of cultured ovine B cells following retroviral vector-mediated delivery of Tax(BLV). Using cDNA-spotted microarrays comprising 10,336 human genes/expressed sequence tags, we identified a cohort of differentially expressed genes, including genes related to apoptosis, DNA transcription, and repair; proto-oncogenes; cell cycle regulators; transcription factors; small Rho GTPases/GTPase-binding proteins; and previously reported Tax(HTLV-1)-responsive genes. Interestingly, genes known to be associated with human neoplasia, especially B-cell malignancies, were extensively represented. Others were novel or unexpected. The results suggest that Tax(BLV) deregulates a broad network of interrelated pathways rather than a single B-lineage-specific regulatory process. Although cross-species approaches do not permit a comprehensive analysis of gene expression patterns, they can provide initial clues for the functional roles of genes that participate in B-cell transformation and pinpoint molecular targets not identified using other methods in animal models.
Collapse
Affiliation(s)
- Pavel Klener
- Laboratory of Experimental Hematology, Bordet Institute, 121 Blvd. de Waterloo, 1000 Brussels, Belgium
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
461
|
Loi S, Sotiriou C, Buyse M, Rutgers E, Van't Veer L, Piccart M, Cardoso F. Molecular Forecasting of Breast Cancer: Time to Move Forward With Clinical Testing. J Clin Oncol 2006; 24:721-2; author reply 722-3. [PMID: 16446348 DOI: 10.1200/jco.2005.04.6524] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
462
|
Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005; 16:1723-39. [PMID: 15980158 DOI: 10.1093/annonc/mdi352] [Citation(s) in RCA: 203] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
In the last few decades, proliferative markers have been broadly evaluated as prognostic and predictive factors for early stage breast cancer patients. Several papers evaluating one or more markers have been published, often with contradictory results. As a consequence, there is still uncertainty about the role of these proliferative markers. The present paper critically reviews the current knowledge about the following markers: thymidine labeling index, S phase fraction/flow cytometry, Ki 67, thymidine kinase (TK), cyclins E, cyclin D, the cyclin inhibitors p27 and p21, and topoisomerase IIalpha. For each marker, the prognostic and predictive role was separately analyzed. Only papers published in English in peer-reviewed journals before June 2004 that include at least 100 evaluable patients were selected. In addition, the prognostic and predictive role of the proliferative markers had to be assessed through multivariate analyses. One hundred and thirty-two papers fulfilled these criteria and 159 516 patients were analyzed. Unfortunately, several methodological problems in the research to date prevent us from including any one of these proliferative markers among the standard prognostic and predictive factors. Early incorporation of translational research and new technologies with clinical trials are needed to prospectively validate biological markers and allow their use in clinical practice.
Collapse
Affiliation(s)
- M Colozza
- S. C. Oncologia Medica, Azienda Ospedaliera, San Sisto 06132 Perugia, Italy
| | | | | | | | | | | |
Collapse
|
463
|
Jazaeri AA, Awtrey CS, Chandramouli GVR, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 2005; 11:6300-10. [PMID: 16144934 DOI: 10.1158/1078-0432.ccr-04-2682] [Citation(s) in RCA: 150] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE The goal of this study was to determine whether distinct gene expression profiles are associated with intrinsic and/or acquired chemoresistance in epithelial ovarian carcinoma. EXPERIMENTAL DESIGN Gene expression profiles were generated from 21 primary chemosensitive tumors and 24 primary chemo-resistant tumors using cDNA-based microarrays. Gene expression profiles of both groups of primary tumors were then compared with those of 15 ovarian carcinomas obtained following platinum-based chemotherapy ("post-chemotherapy" tumors). A theme discovery tool was used to identify functional categories of genes involved in drug resistance. RESULTS Comparison of primary chemosensitive and chemo-resistant tumors revealed differential expression of 85 genes (P < 0.001). Comparison of gene expression profiles of primary chemosensitive tumors and post-chemotherapy tumors revealed more robust differences with 760 genes differentiating the two groups (P < 0.001). In contrast, only 230 genes were differentially expressed between primary chemo-resistant and post-chemotherapy groups (P < 0.001). Common to both gene lists were 178 genes representing transcripts differentially expressed between post-chemotherapy tumors and all primary tumors irrespective of intrinsic chemosensitivity. The gene expression profile of post-chemotherapy tumors compared with that of primary tumors revealed statistically significant overrepresentation of genes encoding extracellular matrix-related proteins. CONCLUSIONS These data show that gene expression profiling can discriminate primary chemo-resistant from primary chemosensitive ovarian cancers. Gene expression profiles were also identified that correlate with states of intrinsic and acquired chemoresistance and that represent targets for future investigation and potential therapeutic interventions.
Collapse
Affiliation(s)
- Amir A Jazaeri
- Laboratory of Biosystems and Cancer, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
464
|
Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-Galdon M, Veys I, Cardoso F, Sotiriou C, Di Leo A, Piccart MJ, Larsimont D. Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice. Clin Cancer Res 2005; 11:4393-9. [PMID: 15958623 DOI: 10.1158/1078-0432.ccr-04-2256] [Citation(s) in RCA: 88] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE To assess the effect of chromosome 17 copy number on HER-2/neu status determination in breast cancers. EXPERIMENTAL DESIGN HER-2/neu gene copy and chromosome 17 centromere numbers were evaluated on 893 breast carcinomas using double color fluorescence in situ hybridization (FISH). The net and chromosome 17 corrected (ratio) HER-2/neu copy numbers were compared and related to immunohistochemistry done according to the Food and Drug Administration (FDA)-approved scoring system (0, 1+, 2+, and 3+) as a first screening step in 584 cases. RESULTS When a ratio > or = 2 was considered as criterion for FISH positivity, 49.3% (440 of 893) of cases showed amplification versus 56.2% (502 of 893) by using a net HER-2/neu gene copy number >4 as a alternative criterion; 14.8% (67 of 453) of cases having a ratio <2 had a net HER-2/neu gene copy number >4 and 1.1% (5 of 440) with a ratio > or = 2 had a net HER-2/neu gene copy number <4. Among discordant cases, 88.8% (64 of 72) were polysomic (>2.25 chromosomes 17/cell) and among polysomic cases, 12.8% (40 of 312) of the low polysomic (2.26-3.75 chromosomes 17/cell) and 36.9% (24 of 65) of the highly polysomic (>3.75 chromosomes 17/cell) cases showed discordance. In cases with a ratio <2, polysomy 17 incidences were 85.7% (6 of 7) in IHC 3+, 42.4% (79 of 186) in IHC 2+, 33.3% (15 of 45) in IHC 1+, and 29.1% (16 of 55) in IHC 0. CONCLUSION A net increase in HER-2/neu gene copy number consecutive to polysomy 17 in the absence of specific gene amplification might lead to a strong protein overexpression in a small subset of breast carcinomas. HER-2/neu status determination by FISH is dependent on the criterion considered for positivity in clinical practice.
Collapse
Affiliation(s)
- Yan Ma
- Pathology Department, Institut Jules Bordet, Brussels, Belgium
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
465
|
Loi S, Piccart M, Haibe-Kains B, Desmedt C, Harris AL, Bergh J, Tutt A, Miller LD, Liu ET, Sotiriou C. Prediction of early distant relapses on tamoxifen in early-stage breast cancer (BC): A potential tool for adjuvant aromatase inhibitor (AI) tailoring. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.509] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Loi
- Jules Bordet Institute, Brussels, Belgium; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden; Guys Hosp, London, United Kingdom; Genome Institute of Singapore, Singapore, Singapore
| | - M. Piccart
- Jules Bordet Institute, Brussels, Belgium; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden; Guys Hosp, London, United Kingdom; Genome Institute of Singapore, Singapore, Singapore
| | - B. Haibe-Kains
- Jules Bordet Institute, Brussels, Belgium; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden; Guys Hosp, London, United Kingdom; Genome Institute of Singapore, Singapore, Singapore
| | - C. Desmedt
- Jules Bordet Institute, Brussels, Belgium; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden; Guys Hosp, London, United Kingdom; Genome Institute of Singapore, Singapore, Singapore
| | - A. L. Harris
- Jules Bordet Institute, Brussels, Belgium; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden; Guys Hosp, London, United Kingdom; Genome Institute of Singapore, Singapore, Singapore
| | - J. Bergh
- Jules Bordet Institute, Brussels, Belgium; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden; Guys Hosp, London, United Kingdom; Genome Institute of Singapore, Singapore, Singapore
| | - A. Tutt
- Jules Bordet Institute, Brussels, Belgium; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden; Guys Hosp, London, United Kingdom; Genome Institute of Singapore, Singapore, Singapore
| | - L. D. Miller
- Jules Bordet Institute, Brussels, Belgium; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden; Guys Hosp, London, United Kingdom; Genome Institute of Singapore, Singapore, Singapore
| | - E. T. Liu
- Jules Bordet Institute, Brussels, Belgium; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden; Guys Hosp, London, United Kingdom; Genome Institute of Singapore, Singapore, Singapore
| | - C. Sotiriou
- Jules Bordet Institute, Brussels, Belgium; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden; Guys Hosp, London, United Kingdom; Genome Institute of Singapore, Singapore, Singapore
| |
Collapse
|
466
|
Sotiriou C, Wirapati P, Loi S, Desmedt C, Harris AL, Bergh J, Smeds J, Cardoso F, Delorenzi M, Piccart M. Molecular characterization of clinical grade in breast cancer (BC) challenges the existence of “grade 2” tumors. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.506] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Sotiriou
- Jules Bordet Institute, Brussels, Belgium; ISREC, Epalinges, Lausanne, Switzerland; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden
| | - P. Wirapati
- Jules Bordet Institute, Brussels, Belgium; ISREC, Epalinges, Lausanne, Switzerland; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden
| | - S. Loi
- Jules Bordet Institute, Brussels, Belgium; ISREC, Epalinges, Lausanne, Switzerland; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden
| | - C. Desmedt
- Jules Bordet Institute, Brussels, Belgium; ISREC, Epalinges, Lausanne, Switzerland; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden
| | - A. L. Harris
- Jules Bordet Institute, Brussels, Belgium; ISREC, Epalinges, Lausanne, Switzerland; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden
| | - J. Bergh
- Jules Bordet Institute, Brussels, Belgium; ISREC, Epalinges, Lausanne, Switzerland; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden
| | - J. Smeds
- Jules Bordet Institute, Brussels, Belgium; ISREC, Epalinges, Lausanne, Switzerland; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden
| | - F. Cardoso
- Jules Bordet Institute, Brussels, Belgium; ISREC, Epalinges, Lausanne, Switzerland; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden
| | - M. Delorenzi
- Jules Bordet Institute, Brussels, Belgium; ISREC, Epalinges, Lausanne, Switzerland; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden
| | - M. Piccart
- Jules Bordet Institute, Brussels, Belgium; ISREC, Epalinges, Lausanne, Switzerland; John Radcliff Hosp, Oxford, United Kingdom; Karolinska Institute, Stockholm, Sweden
| |
Collapse
|
467
|
Ravoet M, Sibille C, Roufosse F, Duvillier H, Sotiriou C, Schandené L, Martiat P, Goldman M, Willard-Gallo KE. 6q- is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome. Haematologica 2005; 90:753-65. [PMID: 15951288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2023] Open
Abstract
BACKGROUND AND OBJECTIVES The lymphocytic variant of hypereosinophilic syndrome (LV-HES) is an underrated disease defined by the monoclonal proliferation of interleukin-5 secreting T-cells. This disease is distinguished by a period of chronic lymphoproliferation without clinical transformation, which is frequently a precursor to T-cell lymphoma. In this study, LV-HES was used as a model of pre-malignancy to identify specific marker(s) predictive of the potential for malignant transformation. DESIGN AND METHODS The karyotypic abnormalities detected in the abnormal CD3-CD4+ T cells were further characterized by fluorescent in situ hybridization. A multi-step retrospective analysis was performed on successive blood samples during a six-year follow up to correlate the evolution of cytogenetic changes with clinical progression. Expression array analysis was used to investigate the effect of these chromosomal aberrations on gene expression. RESULTS A 6q deletion was detected in the two LV-HES patients during their chronic disease phase. An additional 10p deletion was found alone or in association with the 6q defect in one patient prior to the development of a CD3-CD4+ T-cell lymphoma six years after diagnosis. We show that the 6q but not the 10p deletion is both stable and persistent throughout the chronic disease, finally emerging as the predominant aberration in the lymphoma cells. Six genes mapped to the 6q-deleted region displayed altered gene expression profiles both in the chronic and malignant disease phases. INTERPRETATION AND CONCLUSIONS Our data suggest that the 6q deletion represents an early cytogenetic marker for T-cell transformation.
Collapse
Affiliation(s)
- Marie Ravoet
- Center for Human Genetics, Cliniques Universitaires St Luc UCL, Brussels, Belgium
| | | | | | | | | | | | | | | | | |
Collapse
|
468
|
Symmans WF, Sotiriou C, Anderson KS, Valero V, Booser DJ, Hess KR, Ross JS, Piccart M, Hortobagyi GN, Pusztai L. Use of DNA microarrays to determine estrogen and HER-2 receptor status in breast cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- W. F. Symmans
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - C. Sotiriou
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - K. S. Anderson
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - V. Valero
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - D. J. Booser
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - K. R. Hess
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - J. S. Ross
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - M. Piccart
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - G. N. Hortobagyi
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - L. Pusztai
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| |
Collapse
|
469
|
Abstract
In the past 30 years, important advances have been made in the knowledge of breast cancer biology and in the treatment of the disease. However, the translation of these advances into clinical practice has been slow. With the advent of molecular-based medicine, it is hoped that the bridge between the bench and the bedside will continue to be shortened. Because breast cancer is a heterogeneous disease with wide-ranging subsets of patients who have different prognoses and who respond differently to treatments, the identification of patients who need treatment and the definition of the best therapy for an individual have become the priorities in breast cancer care. This article will review the crucial role of prognostic and predictive factors in achieving these goals. A critical review of classical and newer individual molecular markers, such as hormone receptors, HER2, urokinase-type plasminogen activator and plasminogen activator inhibitor 1, cyclin E, topoisomerase II, and p53, was performed, and the preliminary results obtained using the new gene expression profiling technology are described along with their potential clinical implications.
Collapse
|
470
|
Lacroix M, Haibe-Kains B, Hennuy B, Laes JF, Lallemand F, Gonze I, Cardoso F, Piccart M, Leclercq G, Sotiriou C. Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes. Oncol Rep 2005; 12:701-7. [PMID: 15375488 DOI: 10.3892/or.12.4.701] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We have examined the effects of the protein kinase C (PKC)-activator phorbol 12-myristate 13-acetate (PMA) on gene expression in two breast cancer cell (BCC) lines exhibiting highly different phenotypes. These are the estrogen receptor alpha (ERalpha)-positive, weakly invasive, luminal epithelial-like MCF-7 and the ERalpha-negative, highly invasive, fibroblast-like MDA-MB-231. They express constitutively low and high PKC activities, respectively. After a 24-h exposition to 100 nM PMA, the number of genes showing an altered expression at the 2-fold change level was much higher in MCF-7 (n=435) than in MDA-MB-231 (n=18) BCC. Four of these genes, namely CDC2, CENPA, NR4A1 and MMP10, were altered in the same way in both cell lines. Two genes were regulated in an opposite way: ID1 and EVA1. Many of the genes down-regulated in MCF-7 BCC appeared to be preferentially expressed in the G1, S, and/or G2 phases of the cell cycle. The ERalpha gene, ESR1, and other genes associated to the ERalpha-positive, luminal epithelial-like BCC phenotype were down-regulated, while a series of genes related to a more aggressive, fibroblast-like BCC phenotype were up-regulated. Other altered genes were notably linked to cell architecture, supporting profound effects of PMA on cell morphology and motility, as well as on the interactions between BCC and their neighboring proteins. Of note, all the modulated genes involved in proteolysis and its control were up-regulated. In summary, PMA effects suggest that PKC activation may induce, to some extent, a more fibroblast-like phenotype in the ERalpha-positive, luminal epithelial-like MCF-7 BCC, and significantly modulate the interactions of these cells with their environment.
Collapse
Affiliation(s)
- M Lacroix
- Laboratoire Jean-Claude Heuson de Cancérologie Mammaire, Institut Jules Bordet, Free University of Brussels, Brussels, Belgium.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
471
|
Durbecq V, Desmed C, Paesmans M, Cardoso F, Di Leo A, Mano M, Rouas G, Leroy JY, Sotiriou C, Piccart M, Larsimont D. Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer. Int J Oncol 2005; 25:1473-9. [PMID: 15492841 DOI: 10.3892/ijo.25.5.1473] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Topoisomerase-IIalpha (topo-II) is a molecular target for topo-II inhibitors, which makes it a potential predictive marker of responsiveness to these agents. We aim to correlate topo-II gene and protein status on 103 HER-2 amplified breast cancer samples. Paraffin-embedded blocks were screened by FISH for topo-II gene amplification (topo-II: CEP17 ratio >/=1.5; triple probe by Vysis inc.) and analyzed by IHC for topo-II protein expression (continuous variable; clone KiS1) and Ki-67 (positive if >25% of stained cells; clone MIB-1). Topo-II gene amplification was observed in 36.9% (38/103) of the HER-2 amplified study population. HER-2 amplification level (e.g. copy number) was not shown to be predictive for topo-II amplification. The median percentage of topo-II positively stained cells by IHC for topo-II non-amplified and amplified cases were 5% and 10%, respectively. A weak but significant correlation was observed between topo-II gene amplification level and percentage of positively stained cells (Spearman's ranks correlation coefficient of 0.23, p=0.02), the observed correlation being higher in patients with positive staining for Ki-67. Contrary to HER-2, where gene amplification is almost always correlated with protein overexpression in breast cancer, topo-II gene amplification apparently does not always lead to protein overexpression, at least when the latter is evaluated by IHC. Other factors, specifically the tumor proliferation status, may interfere with the topo-II protein status. Although the great majority of topo-II gene aberrations occur in HER-2 positive tumors, the level of HER-2 amplification does not predict for topo-II amplification.
Collapse
Affiliation(s)
- V Durbecq
- Translational Research Unit, Jules Bordet Institute, Boulevard de Waterloo 125, 1000 Brussels, Belgium
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
472
|
Abstract
The advent of high-throughput array-based technology and the sequencing of the human genome has provided the opportunity to begin comprehensive molecular and genetic profiling of cancers. Such efforts have, in a limited time, given us new insights into breast cancer biology and confirmed that the disease is considerably more heterogeneous than can be predicted by traditional histopathological methods. The estrogen receptor has been found to be the most dominant factor influencing the molecular composition of breast cancer and, in addition, novel subgroups of breast cancer with differing clinical outcomes have been observed. These may have substantial management implications for breast cancer patients and facilitate individualized rather than empirical oncological prescription. Furthermore, new methods of prognostic classification have been developed using array technology. The challenges ahead lie in refining the use of the technology, proper validation of discoveries, and the large-scale collaborative efforts necessary for the incorporation of genomic knowledge into the design and conduct of clinical trials. This will lead, ultimately, to the application of user-friendly tools derived from this technology to everyday patient care.
Collapse
Affiliation(s)
- Sherene Loi
- Jules Bordet Institute, Microarray Laboratories, Department of Medical Oncology, 121 Boulevard de Waterloo, Brussels 1000, Belgium
| | | | | | | | | |
Collapse
|
473
|
Cardoso F, Paesmans M, Larsimont D, Durbecq V, Bernard-Marty C, Rouas G, Dolci S, Sotiriou C, Piccart MJ, Di Leo A. Potential Predictive Value of Bcl-2 for Response to Tamoxifen in the Adjuvant Setting of Node-Positive Breast Cancer. Clin Breast Cancer 2004; 5:364-9. [PMID: 15585074 DOI: 10.3816/cbc.2004.n.043] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Approximately 50% of patients with estrogen receptor (ER)-positive breast cancer (BC) and 70%-80% of patients with ER-positive and progesterone receptor (PgR)-positive BC respond to hormonal therapy. Additional predictive markers are needed. A group of 287 patients with ER- and/or PgR-positive tumors was selected from 804 patients previously enrolled in a multicenter phase III trial. Bcl-2 expression was evaluated and correlated with response to adjuvant tamoxifen and survival. Estrogen receptor and PgR were determined by biochemical means and Bcl-2 by immunohistochemistry. With a median follow-up of 76 months (95 relapses and 60 deaths), of the 287 patients with, 187 (65%) had Bcl-2-positive tumors and 78 of these patients received tamoxifen. Of the 100 patients with Bcl-2-negative disease, 51 received tamoxifen and 49 regular follow-up. Using patients treated with tamoxifen as a reference, a univariate analysis of disease-free interval for patients who did not receive tamoxifen showed a hazard ratio (HR) of 1.42 (95% CI, 0.82-2.44; P = 0.21) for patients with Bcl-2-positive disease and a HR of 1.05 (95% CI, 0.55-1.99; P = 0.89) for patients with Bcl-2-negative disease (P = 0.48). After adjusting for number of positive lymph nodes, degree of receptor and PgR positivity, and type of surgery, the HRs were 1.54 (95% CI, 0.87-2.73; P = 0.14) for Bcl-2-positive disease and 1.05 (95% CI, 0.52-2.11; P = 0.88) for Bcl-2-negative disease. Despite its being a retrospective nonrandomized study with a relatively low number of patients, our results suggest that Bcl-2 deserves further evaluation as a predictive factor of sensitivity to tamoxifen.
Collapse
Affiliation(s)
- Fatima Cardoso
- Translational Research Unit, Jules Bordet Institute, Brussels, Belgium.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
474
|
Abstract
PURPOSE OF REVIEW Head and neck squamous cell carcinoma is the fifth most common cancer worldwide. Unfortunately, patients with the same diagnostic and prognostic profile can have markedly different clinical outcomes. This most likely results from the fact that the current taxonomy of head and neck squamous cell carcinoma groups molecularly different diseases with distinct clinical phenotypes into classifications based mainly on morphology. A combination of circumstances, including the advent of array-based technology and progress in the human genome initiative, now provides an ideal opportunity to begin performing comprehensive molecular and genetic profiling of head and neck squamous cell carcinoma. This article reviews recently reported studies that have used such approaches. RECENT FINDINGS Comparison of gene expression profiles between head and neck squamous cell carcinoma and normal tissues showed altered expression levels of genes involved in the control of cell growth and differentiation, angiogenesis, apoptosis, cell cycle, and signaling, most of which have not been previously described in head and neck squamous cell carcinoma. Additionally, they revealed the implication of different signaling and metabolic pathways such wnt and noch, highlighting the potential role of these pathways in oral cancer development. Their results provide new insights into the carcinogenesis of head and neck squamous cell carcinoma as well as a source of potential prognostic and predictive markers and targets for its prevention and therapeutics. SUMMARY Although the sample sizes of these studies were small and their findings therefore require further validation in larger trials, such preliminary results provide important clues to the understanding of the various gene networks implicated in oral carcinogenesis and may contribute to the selection of target genes for possible molecular diagnosis and therapy in the future.
Collapse
Affiliation(s)
- C Sotiriou
- Translational Unit, Jules Bordet Institute, Brussels, Belgium.
| | | | | | | | | |
Collapse
|
475
|
Abstract
PURPOSE OF REVIEW Clinical trials in breast cancer (BC) have seldom taken into consideration molecular heterogeneity, because most have been performed in unselected populations. Hence, their results provide an estimated average benefit for the entire BC population, which may not always be translated to subsets of patients with certain characteristics, let alone to individual patients. Further understanding and acknowledgment of heterogeneity is vital for the development of individualized therapy in BC. New approaches are needed for trial design, patient selection, and choice of endpoints (including surrogate markers). The neoadjuvant setting presents a unique opportunity to test new concepts in a previously untreated patient population, because they may yield preliminary answers in a shorter time than that required in adjuvant trials. RECENT FINDINGS The importance of patient selection in the development of targeted agents is exemplified by trastuzumab in BC and of gefitinib in lung cancer. Ongoing innovative trials that investigate biologic hypotheses include the BIG-EORTC p53, TOP and FRAGRANCE trials (which study predictive factors for response), and the NNBC-3 and MINDACT trials (which study prognostic factors). SUMMARY There is an urgent need to break from traditional clinical development and to incorporate new molecular knowledge and translational research in the design of clinical trials. The success of new approaches in BC research critically depends on well-conducted translational research linked to prospective clinical trials, and international collaboration, bringing together human and technological resources.
Collapse
Affiliation(s)
- Sherene Loi
- Translational Research Unit, Jules Bordet Institute, 121 Boulevard de Waterloo, Brussels 1000, Belgium
| | | | | | | |
Collapse
|
476
|
Abstract
The 26S proteasome is an adenosine triphosphate-dependent multicatalytic protease that is responsible for most nonlysosomal intracellular protein degradation. To be selected for proteasomal degradation, proteins must be previously tagged with a polyubiquitin chain, which is then recognized by the proteasome; the ubiquitin chain is removed by isopeptidases and the protein is hydrolysed to small polypeptides. In addition to removing damaged/unnecessary proteins, the proteasome is also an important mechanism of regulation of some key regulatory proteins and their inhibitors. This regulation is crucial for the control of many cellular processes, including activation of transcription factors, cell cycle progression, and apoptosis. The critical role of the ubiquitin-proteasome pathway in tumor cells has led to the investigation of proteasome inhibition as a potential anticancer therapy. The dipeptide boronic acid analogue bortezomib, formerly known as PS-341, is a potent, highly selective, and reversible proteasome inhibitor. The first drug of this class to be used in the clinical setting, it has recently been approved by the US Food and Drug Administration for the treatment of relapsed and refractory multiple myeloma and is currently being tested in clinical trials for the treatment of a wide variety of malignancies. This article provides a summary of the biology of the ubiquitin-proteasome pathway, reviews the available preclinical and clinical data of proteasome inhibition as a therapeutic strategy in breast cancer, and discusses future combination regimens involving bortezomib.
Collapse
Affiliation(s)
- Fatima Cardoso
- Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium.
| | | | | | | | | |
Collapse
|
477
|
Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, Friedrichs K, Pinter T, Van Belle S, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Perren TJ, Leroy JY, Rouas G, Sotiriou C, Piccart M, Larsimont D. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther 2004; 3:1207-14. [PMID: 15486187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
PURPOSE The predictive value of topoisomerase-II alpha (topo-II) has been evaluated in advanced breast cancer patients randomly treated with single-agent doxorubicin or docetaxel. EXPERIMENTAL DESIGN Primary tumor samples from patients enrolled in a randomized, phase III clinical trial comparing single-agent doxorubicin (75 mg/m(2) q3wks) with docetaxel (100 mg/m(2) q3wks) were collected and topo-II status was evaluated by immunohistochemistry (clone KiS1). RESULTS Topo-II status was evaluated in 108 samples, 55 (51%) in the doxorubicin arm and 53 (49%) in the docetaxel arm. An increment of 10% in cells expressing topo-II is associated with a statistically significant odds ratio (OR; 95% confidence interval) of 1.09 (1.03-1.15; P = 0.002) for overall response to doxorubicin versus 1.002 (0.94-1.07; P = 0.95) in the docetaxel arm. With increasing topo-II, the favorable OR for overall response to docetaxel compared with doxorubicin decreases to become not significant in patients with topo-II tumor content >10%. In a multivariate analysis, (a) HER-2 status seems positively correlated with overall response to chemotherapy (OR, 2.34; 95% confidence interval, 0.87-6.27; P = 0.09). (b) Overall response to doxorubicin is significantly lower than overall response to docetaxel (OR, 0.17; 95% confidence interval, 0.04-0.64; P = 0.009) but with a significant interaction term for doxorubicin-treated patients with topo-II tumor content >10% (OR, 8.31; 95% confidence interval, 1.86-37.03; P = 0.05). CONCLUSIONS (a) Topo-II overexpression confers a higher probability of response in the doxorubicin arm only. (b) Despite being a small retrospective study, this study is in line with previously reported studies and the hypotheses raised are now being tested in a prospective neoadjuvant trial.
Collapse
Affiliation(s)
- Virginie Durbecq
- Jules Bordet Institute, 125 Boulevard de Waterloo, 1000 Brussels, Belgium
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
478
|
Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, Friedrichs K, Pinter T, Van Belle S, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Perren TJ, Leroy JY, Rouas G, Sotiriou C, Piccart M, Larsimont D. Topoisomerase-IIα expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther 2004. [DOI: 10.1158/1535-7163.1207.3.10] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: The predictive value of topoisomerase-IIα (topo-II) has been evaluated in advanced breast cancer patients randomly treated with single-agent doxorubicin or docetaxel. Experimental design: Primary tumor samples from patients enrolled in a randomized, phase III clinical trial comparing single-agent doxorubicin (75 mg/m2 q3wks) with docetaxel (100 mg/m2 q3wks) were collected and topo-II status was evaluated by immunohistochemistry (clone KiS1). Results: Topo-II status was evaluated in 108 samples, 55 (51%) in the doxorubicin arm and 53 (49%) in the docetaxel arm. An increment of 10% in cells expressing topo-II is associated with a statistically significant odds ratio (OR; 95% confidence interval) of 1.09 (1.03–1.15; P = 0.002) for overall response to doxorubicin versus 1.002 (0.94–1.07; P = 0.95) in the docetaxel arm. With increasing topo-II, the favorable OR for overall response to docetaxel compared with doxorubicin decreases to become not significant in patients with topo-II tumor content >10%. In a multivariate analysis, (a) HER-2 status seems positively correlated with overall response to chemotherapy (OR, 2.34; 95% confidence interval, 0.87–6.27; P = 0.09). (b) Overall response to doxorubicin is significantly lower than overall response to docetaxel (OR, 0.17; 95% confidence interval, 0.04–0.64; P = 0.009) but with a significant interaction term for doxorubicin-treated patients with topo-II tumor content >10% (OR, 8.31; 95% confidence interval, 1.86–37.03; P = 0.05). Conclusions: (a) Topo-II overexpression confers a higher probability of response in the doxorubicin arm only. (b) Despite being a small retrospective study, this study is in line with previously reported studies and the hypotheses raised are now being tested in a prospective neoadjuvant trial.
Collapse
Affiliation(s)
| | | | | | | | | | - Stephen Chan
- 2Nottingham City Hospital, Nottingham, United Kingdom
| | - Kay Friedrichs
- 3Universitäts-Frauenklinik und Poliklinic, Hamburg, Germany
| | | | | | | | | | - Euan Walpole
- 8Princess Alexandra Hospital, Brisbane, Queensland, Australia
| | | | - Stefan Korec
- 10National Cancer Institute, Bratislava, Slovakia
| | - John Crown
- 11St. Vincent's Hospital, Dublin, Ireland
| | - Peter Simmonds
- 12Southampton General Hospital, Southampton, United Kingdom; and
| | | | | | | | | | | | | |
Collapse
|
479
|
Jazaeri AA, Chandramouli GVR, Aprelikova O, Nuber UA, Sotiriou C, Liu ET, Ropers HH, Yee CJ, Boyd J, Barrett JC. BRCA1-mediated repression of select X chromosome genes. J Transl Med 2004; 2:32. [PMID: 15383145 PMCID: PMC520825 DOI: 10.1186/1479-5876-2-32] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2004] [Accepted: 09/21/2004] [Indexed: 12/27/2022] Open
Abstract
Recently BRCA1 has been implicated in the regulation of gene expression from the X chromosome. In this study the influence of BRCA1 on expression of X chromosome genes was investigated. Complementary DNA microarrays were used to compare the expression levels of X chromosome genes in 18 BRCA1-associated ovarian cancers to those of the 13 "BRCA1-like" and 14 "BRCA2-like" sporadic tumors (as defined by previously reported expression profiling). Significance was determined using parametric statistics with P < 0.005 as a cutoff. Forty of 178 total X-chromosome transcripts were differentially expressed between the BRCA1-associated tumors and sporadic cancers with a BRCA2-like molecular profile. Thirty of these 40 genes showed higher mean expression in the BRCA1-associated samples including all 11 transcripts that mapped to Xp11. In contrast, four of 178 total X chromosome transcripts showed significant differential expression between BRCA1-associated and sporadic tumors with a BRCA1-like molecular profile. All four mapped to Xp11 and showed higher mean expression in BRCA1-associated tumors. Re-expression of BRCA1 in HCC1937 BRCA1-deficient breast cancer cell resulted in the repression of 21 transcripts. Eleven of the 21 (54.5%) transcripts mapped to Xp11. However, there was no significant overlap between these Xp11 genes and those found to be differentially expressed between BRCA1-associated and sporadic ovarian cancer samples. These results demonstrate that BRCA1 mediates the repression of several X chromosome genes, many of which map to the Xp11 locus.
Collapse
Affiliation(s)
- Amir A Jazaeri
- From the Center for Cancer Research of the National Cancer Institute. Building 31, Room 3A11, 31 Center Drive, MSC 2440, Bethesda, MD 20892-2440 USA
| | - Gadisetti VR Chandramouli
- From the Center for Cancer Research of the National Cancer Institute. Building 31, Room 3A11, 31 Center Drive, MSC 2440, Bethesda, MD 20892-2440 USA
| | - Olga Aprelikova
- From the Center for Cancer Research of the National Cancer Institute. Building 31, Room 3A11, 31 Center Drive, MSC 2440, Bethesda, MD 20892-2440 USA
| | - Ulrike A Nuber
- Max Planck Institute for Molecular Genetics. Ihnestrasse 73, 14195 Berlin Germany
| | - Christos Sotiriou
- From the Center for Cancer Research of the National Cancer Institute. Building 31, Room 3A11, 31 Center Drive, MSC 2440, Bethesda, MD 20892-2440 USA
- Jules Bordet Institute. Microarray Unit, 121 Bld. de Waterloo, 1000 Brussels, Belgium
| | - Edison T Liu
- From the Center for Cancer Research of the National Cancer Institute. Building 31, Room 3A11, 31 Center Drive, MSC 2440, Bethesda, MD 20892-2440 USA
- Genome Institute of Singapore, 1 Science Park Rd., The Capricorn #05-01, Singapore Sicence Park II 117528, Singapore
| | - H Hilger Ropers
- Max Planck Institute for Molecular Genetics. Ihnestrasse 73, 14195 Berlin Germany
| | - Cindy J Yee
- From the Departments of Surgery and Medicine of the Memorial Sloan-Kettering Cancer Center 1275 York Ave., New York, New York, 10021 USA
| | - Jeff Boyd
- From the Departments of Surgery and Medicine of the Memorial Sloan-Kettering Cancer Center 1275 York Ave., New York, New York, 10021 USA
| | - J Carl Barrett
- From the Center for Cancer Research of the National Cancer Institute. Building 31, Room 3A11, 31 Center Drive, MSC 2440, Bethesda, MD 20892-2440 USA
| |
Collapse
|
480
|
Sotiriou C, Paesmans M, Harris A, Colozza MA, Fox S, Taylor M, Sorre A, Martiat P, Cardoso F, Piccart M. Cyclin E1 (CCNE1) and E2 (CCNE2) as prognostic and predictive markers for endocrine therapy (ET) in early breast cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9504] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Sotiriou
- Jules Bordet Institute, Brussels, Belgium; ICRF, John Radcliffe Hospital, Oxford, United Kingdom
| | - M. Paesmans
- Jules Bordet Institute, Brussels, Belgium; ICRF, John Radcliffe Hospital, Oxford, United Kingdom
| | - A. Harris
- Jules Bordet Institute, Brussels, Belgium; ICRF, John Radcliffe Hospital, Oxford, United Kingdom
| | - M. A. Colozza
- Jules Bordet Institute, Brussels, Belgium; ICRF, John Radcliffe Hospital, Oxford, United Kingdom
| | - S. Fox
- Jules Bordet Institute, Brussels, Belgium; ICRF, John Radcliffe Hospital, Oxford, United Kingdom
| | - M. Taylor
- Jules Bordet Institute, Brussels, Belgium; ICRF, John Radcliffe Hospital, Oxford, United Kingdom
| | - A. Sorre
- Jules Bordet Institute, Brussels, Belgium; ICRF, John Radcliffe Hospital, Oxford, United Kingdom
| | - P. Martiat
- Jules Bordet Institute, Brussels, Belgium; ICRF, John Radcliffe Hospital, Oxford, United Kingdom
| | - F. Cardoso
- Jules Bordet Institute, Brussels, Belgium; ICRF, John Radcliffe Hospital, Oxford, United Kingdom
| | - M. Piccart
- Jules Bordet Institute, Brussels, Belgium; ICRF, John Radcliffe Hospital, Oxford, United Kingdom
| |
Collapse
|
481
|
Abstract
In the last few months, there have been three sets of new, provocative data that might have important implications for the daily prescription of adjuvant chemotherapy (CT) in the future. (1) Urokinase-type plasminogen activator (UPA) and type 1 plasminogen activator inhibitor (PAI-1), two molecular markers of invasion already known for their powerful prognostic value in node-negative breast cancer, seem to predict for enhanced benefit from adjuvant CT, while the benefit from adjuvant endocrine therapy seems independent of them. The predictive value of these markers, however, remains suboptimal and an important limitation lies in their evaluation through a cytosolic assay, which is compromised for small tumours (<1cm). (2) Breast cancer 'gene expression profiles' have been identified through DNA-microarray technology and seem to be better predictors of clinical outcome in young women (less than 55 years old) with stage I or II breast cancer, when compared to the currently used clinical-pathological criteria. Remarkably, these molecular data suggest that the prognostic profile of breast cancer does not depend on lymph node status and that it is possible to identify a group of node-positive breast cancer patients with an unexpectedly good prognosis. Prospective and independent confirmation is needed, but these data are fascinating and carry the hope that CT decision-making in breast cancer will be greatly facilitated in the future. (3) The recently reported CALGB 9741 (or INT 69741) trial shakes our belief that 'one cycle of CT every 3 weeks' is the adequate adjuvant treatment for node-positive breast cancer. Launched in 1999, it aimed to test two novel concepts based on mathematical models of tumour cell growth kinetics. Concept 1 implies that dose-densification of CT, i.e., delivering drugs at reduced intervals, will maximize the chances of eradicating the tumour; and concept 2 extends the first one to encompass situations of heterogeneous drug sensitivity through the use of sequential dose-dense, non-cross-resistant single agents or regimens. The 3-year results of this trial strongly support concept 1; a longer follow-up and a confirmation study are desirable before recommending changes in routine patient care.
Collapse
Affiliation(s)
- M J Piccart
- Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium.
| | | | | |
Collapse
|
482
|
Wykoff CC, Sotiriou C, Cockman ME, Ratcliffe PJ, Maxwell P, Liu E, Harris AL. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br J Cancer 2004; 90:1235-43. [PMID: 15026807 PMCID: PMC2409644 DOI: 10.1038/sj.bjc.6601657] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Gene expression analysis was performed on a human renal cancer cell line (786-0) with mutated VHL gene and a transfectant with wild-type VHL to analyse genes regulated by VHL and to compare with the gene programme regulated by hypoxia. There was a highly significant concordance of the global gene response to hypoxia and genes suppressed by VHL. Cyclin D1 was the most highly inducible transcript and 14-3-3 epsilon was downregulated. There were some genes regulated by VHL but not hypoxia in the renal cell line, suggesting a VHL role independent of hypoxia. However in nonrenal cell lines they were hypoxia regulated. These included several new pathways regulated by hypoxia, including RNase 6PL, collagen type 1 alpha 1, integrin alpha 5, ferritin light polypeptide, JM4 protein, transgelin and L1 cell adhesion molecule. These were not found in a recent SAGE analysis of the same cell line. Hypoxia induced downregulation of Cyclin D1 in nonrenal cells via an HIF independent pathway. The selective regulation of Cyclin D1 by hypoxia in renal cells may therefore contribute to the tissue selectivity of VHL mutation.
Collapse
Affiliation(s)
- C C Wykoff
- Molecular Oncology Laboratories, John Radcliffe Hospital, Weatherall Institute of Molecular Medicine, Cancer Research UK, Oxford OX3 9DS, UK
| | - C Sotiriou
- Division of Clinical Sciences, National Cancer Institute, USA
| | - M E Cockman
- Wellcome Trust Center for Human Genetics, Oxford OX3 7BN, UK
| | - P J Ratcliffe
- Wellcome Trust Center for Human Genetics, Oxford OX3 7BN, UK
| | - P Maxwell
- Wellcome Trust Center for Human Genetics, Oxford OX3 7BN, UK
| | - E Liu
- Division of Clinical Sciences, National Cancer Institute, USA
| | - A L Harris
- Molecular Oncology Laboratories, John Radcliffe Hospital, Weatherall Institute of Molecular Medicine, Cancer Research UK, Oxford OX3 9DS, UK
- Molecular Oncology Laboratories, John Radcliffe Hospital, Weatherall Institute of Molecular Medicine, Cancer Research UK, Oxford OX3 9DS, UK. E-mail:
| |
Collapse
|
483
|
|
484
|
Giuliani R, Paesmans M, Durbecq V, Di Leo A, Larsimont D, Cocquyt V, Majois F, Sotiriou C, Piccart M, Cardoso F. Predictive value of activated tyrosine kinase (Tyr1248) in patients with HER2-overexpressing metastatic breast cancer (MBC) treated with trastuzumab + chemotherapy regimens. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)91006-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
485
|
Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy J, Rouas G, Sotiriou C, Renard N, Richard V, Piccart M, Di Leo A. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-α gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 2004. [DOI: 10.3892/ijo.24.1.201] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
486
|
Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy JY, Rouas G, Sotiriou C, Renard N, Richard V, Piccart MJ, Di Leo A. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 2004; 24:201-9. [PMID: 14654958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023] Open
Abstract
UNLABELLED Anthracycline-based regimens are among the most active but also with greater risk of both acute and long-term side effects, namely cardiotoxicity. Predictive markers of response to anthracyclines are therefore essential. Topoisomerase-IIalpha (topo-II) is the target of anthracyclines and preliminary data suggest its promising role as a predictive marker of sensitivity to these drugs. After screening a population of about 350 patients with locally advanced or metastatic breast cancer, two subgroups were selected for the present analysis: a study group (31 patients), composed of 14 complete responders (CR-a) and 17 true non-responders (PD-a) to anthracycline-based CT, and a control group (28 patients), composed of 7 CR (CR-t) and 21 true non-responders (PD-t) to taxane-based CT. True non-responders were defined as progressive disease (PD) within the first three cycles of CT. Archival tumor samples of these patients were collected, biological markers evaluated and their status correlated with response to therapy. HER-2 and topo-II gene status were evaluated by FISH (Vysis multi-color probe-positivity cut-off: >/=2 ratio for HER-2 and >/=1.5 for topo-II), topo-II protein was evaluated by IHC (positivity cut-off >10%). All cases in which HER-2 gene was non-amplified did not show topo-II gene aberrations. No association was found between HER-2 gene amplification and response to anthracyclines (5/14 (36%) CR and 5/17 (29%) PD to anthracycline-based CT were HER-2+). The topo-II gene was amplified in 3/14 (21%) CR but only in 1/17 (6%) PD to anthracyclines. Amplification of the topo-II gene was seen in 1/7 (14%) CR and in 3/21 (14%) PD to a taxane-based CT. Topo-II protein was overexpressed in 6/11 (55%) CR and in 2/17 (12%) PD to anthracyclines, while in the control group, overexpression was seen in 5/7 (71%) CR and 8/20 (40%) PD. IN CONCLUSION i) HER-2 gene amplification did not seem to be correlated with response to anthracyclines. ii) Both topo-II gene amplification and protein overexpression seem to correlate with response to anthracyclines, although other factors, such as p53 and cell proliferation, are most likely to be involved. iii) The role of combined evaluation of several relevant markers and of potential 'molecular signatures' are currently being evaluated in prospective randomized clinical trials.
Collapse
Affiliation(s)
- F Cardoso
- Translational Research Unit, Department of Medical Oncology, Jules Bordet Institute, 1000 Brussels, Belgium.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
487
|
Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003; 100:10393-8. [PMID: 12917485 PMCID: PMC193572 DOI: 10.1073/pnas.1732912100] [Citation(s) in RCA: 1399] [Impact Index Per Article: 66.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2002] [Indexed: 11/18/2022] Open
Abstract
Comprehensive gene expression patterns generated from cDNA microarrays were correlated with detailed clinico-pathological characteristics and clinical outcome in an unselected group of 99 node-negative and node-positive breast cancer patients. Gene expression patterns were found to be strongly associated with estrogen receptor (ER) status and moderately associated with grade, but not associated with menopausal status, nodal status, or tumor size. Hierarchical cluster analysis segregated the tumors into two main groups based on their ER status, which correlated well with basal and luminal characteristics. Cox proportional hazards regression analysis identified 16 genes that were significantly associated with relapse-free survival at a stringent significance level of 0.001 to account for multiple comparisons. Of 231 genes previously reported by others [van't Veer, L. J., et al. (2002) Nature 415, 530-536] as being associated with survival, 93 probe elements overlapped with the set of 7,650 probe elements represented on the arrays used in this study. Hierarchical cluster analysis based on the set of 93 probe elements segregated our population into two distinct subgroups with different relapse-free survival (P < 0.03). The number of these 93 probe elements showing significant univariate association with relapse-free survival (P < 0.05) in the present study was 14, representing 11 unique genes. Genes involved in cell cycle, DNA replication, and chromosomal stability were consistently elevated in the various poor prognostic groups. In addition, glutathione S-transferase M3 emerged as an important survival marker in both studies. When taken together with other array studies, our results highlight the consistent biological and clinical associations with gene expression profiles.
Collapse
Affiliation(s)
- Christos Sotiriou
- Division of Clinical Sciences, National Cancer Institute, Advanced Technology Center, 8717 Grovemont Circle, Gaithersburg, MD 20877, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
488
|
Seo HS, Journé F, Larsimont D, Sotiriou C, Leclercq G. Decrease of estrogen receptor expression and associated ERE-dependent transcription in MCF-7 breast cancer cells after oligomycin treatment. Steroids 2003; 68:257-69. [PMID: 12628689 DOI: 10.1016/s0039-128x(02)00179-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Oligomycin at 0.01 microM produces very rapid decrease of [3H]estradiol (E2)-binding capacity in MCF-7 cells maintained in culture in glucose- and serum-free medium. Loss of binding capacity was associated with elimination of the estrogen receptor (ER) as well as a decrease of basal expression of ERE-luciferase reporter gene. These effects were not due to major cell death as shown by MTT assay. Hence, the inhibition of ATP synthesis produced by oligomycin seems to influence ER turnover, resulting in very rapid loss of receptor. Withdrawal of oligomycin and maintenance of glucose in the medium led to only a partial reappearance of ER and failed to restore optimal ERE-dependent transcription. Oligomycin significantly down-regulated progesterone receptor (PR) level and partially abrogated E2-induced PR up-regulation, indicating that this drug also affects other nuclear receptors. Treatment of cytosol from MCF-7 cells with acid and alkaline phosphatases decreased [3H]E2-binding capacity, indicating the requirement of ER phosphorylation for optimal hormone binding. On the other hand, oligomycin-induced ER loss was partly compensated by E2 and partial anti-estrogens (AEs; 4-OH-TAM or RU 39 411); i.e. oligomycin failed to improve the E2-induced ER down-regulation and very weakly suppressed partial AE-induced receptor up-regulation. The known ability of these ligands to stabilize ER in the cell nucleus before regulating ER level may explain this phenomenon since such antagonism was not recorded with pure AE RU 58 668, which is known to impede nuclear translocation of the receptor. Interestingly, ligands able to down-regulate ER (i.e. E2 or RU 58 668) increased ER phosphorylation while 4-OH-TAM which up-regulate the receptor had little effect in this regard. Oligomycin failed to strongly affect such phosphorylation enhancements while it produced a weak decrease of basal phosphorylation level. Hence, phosphorylations/dephosphorylations of specific sites on ER and/or co-regulators seem to govern its turnover.
Collapse
Affiliation(s)
- Hye-Sook Seo
- Laboratoire J.-C. Heuson de Cancérologie Mammaire, Service de Médecine Interne, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | | | | | | | | |
Collapse
|
489
|
Pusztai L, Sotiriou C, Buchholz TA, Meric F, Symmans WF, Esteva FJ, Sahin A, Liu ET, Hortobagi GN. Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study. Cancer Genet Cytogenet 2003; 141:148-53. [PMID: 12606133 DOI: 10.1016/s0165-4608(02)00737-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Expression profiling using cDNA microarrays have redefined the molecular classification of some cancers. The comprehensive genetic analysis also permits the identification of novel pathways that might determine subtle differences in tumor phenotype. Herein, we analyzed the tissues from a patient with bilateral cancer of different histologies in each breast (pure invasive mucinous and pure invasive ductal), thus providing a unique opportunity to assess the expression profiles determined by histology in an isogenic human background. Our results show that the mucinous phenotype is associated with the expression of immunostimulatory and inhibitory genes, consistent with the cellular infiltration of lymphocytes and with the expression of enzymes involved in mucin production. Moreover, the panel of matrix metallo-proteinases are distinctly different between the mucinous and the invasive tumors, suggesting that therapeutic targets to this class of compounds may need to be tailored for the varying histologies. Taken together, these data suggest that expression profiling can be used diagnostically to distinguish individual histologic subclassifications and may guide the selection of target therapeutics.
Collapse
Affiliation(s)
- Lajos Pusztai
- Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
490
|
Jazaeri AA, Lu K, Schmandt R, Harris CP, Rao PH, Sotiriou C, Chandramouli GVR, Gershenson DM, Liu ET. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog 2003; 36:53-9. [PMID: 12557260 DOI: 10.1002/mc.10098] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
In epithelial ovarian cancer, tumor grade is an independent prognosticator whose molecular determinants remain unknown. We investigated patterns of gene expression in well- and poorly differentiated serous papillary ovarian and peritoneal carcinomas with cDNA microarrays. A 6500-feature cDNA microarray was used for comparison of the molecular profiles of eight grade III and four grade I stage III serous papillary adenocarcinomas. With a modified F-test in conjunction with random permutations, 99 genes whose expression was significantly different between grade I and grade III tumors were identified (P < 0.01). A disproportionate number of these differentially expressed genes were located on the chromosomal regions 20q13 and all exhibited higher expression in grade III tumors. Interphase fluorescent in situ hybridization demonstrated 20q13 amplification in two of the four grade III and none of the three grade I tumors available for evaluation. Several centrosome-related genes also showed higher expression in grade III tumors. We propose a model in which tumor differentiation is inversely correlated with the overexpression of several oncogenes located on 20q13, a common amplicon in ovarian and numerous other cancers. Dysregulation of centrosome function is one potential mechanistic link between genetic/epigenetic changes and the poorly differentiated phenotype in ovarian cancer.
Collapse
Affiliation(s)
- Amir A Jazaeri
- Center for Cancer Research of the National Cancer Institute, Gaithersburg, Maryland, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
491
|
Di Leo A, Cardoso F, Durbecq V, Giuliani R, Mano M, Atalay G, Larsimont D, Sotiriou C, Biganzoli L, Piccart MJ. Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002. Int J Clin Oncol 2002; 7:245-53. [PMID: 12202978 DOI: 10.1007/s101470200036] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
In the present article, an extensive review of the current knowledge regarding predictive molecular markers in breast cancer is presented. The main emphasis has been given to the adjuvant therapy setting, because of the lack of well-designed studies evaluating predictive markers in the metastatic setting. In the first part of the article some general concepts have been summarized, mainly to emphasize the difference between prognostic and predictive markers. In the second part of the article, studies evaluating molecular markers with predictive value for the most commonly used drugs or regimens (i.e., cyclophosphamide, methotrexate, 5-fluorouracil [CMF], anthracyclines, taxanes, and herceptin) have been reviewed and discussed. An attempt has been made to provide for each single predictive marker the currently available level of evidence, to allow the reader to have immediate information regarding the impact of the evaluated marker in daily clinical practice. In the last part of the article, the most important findings have been summarized and future avenues of research have been outlined.
Collapse
Affiliation(s)
- Angelo Di Leo
- Department of Chemotherapy, Jules Bordet Institute, Brussels, rue Heger-Bordet 1, 1000 Brussels, Belgium.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
492
|
Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002; 94:990-1000. [PMID: 12096084 DOI: 10.1093/jnci/94.13.990] [Citation(s) in RCA: 194] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Germline mutations in BRCA1 and BRCA2 are responsible for 5%-10% of epithelial ovarian cancers, but the molecular pathways affected by these mutations are unknown. We used complementary DNA (cDNA) microarrays to compare gene expression patterns in ovarian cancers associated with BRCA1 or BRCA2 mutations with gene expression patterns in sporadic epithelial ovarian cancers and to identify patterns common to both hereditary and sporadic tumors. METHODS Tumor samples from 61 patients with pathologically confirmed epithelial ovarian adenocarcinoma with matched clinicopathologic features were studied, including 18 with BRCA1 founder mutations, 16 with BRCA2 founder mutations, and 27 without either founder mutation (termed sporadic cancers). The cDNA microarrays contained 7651 sequence-verified features. Gene expression data were analyzed with a modified two-sided F test, with P<.0001 considered statistically significant. The expression level of six genes was also studied with reverse transcription-polymerase chain reaction. RESULTS The greatest contrast in gene expression was observed between tumors with BRCA1 mutations and those with BRCA2 mutations; 110 genes showed statistically significantly different expression levels (P<.0001). This group of genes could segregate sporadic tumors into two subgroups, "BRCA1-like" and "BRCA2-like," suggesting that BRCA1-related and BRCA2-related pathways are also involved in sporadic ovarian cancers. Fifty-three genes were differentially expressed between tumors with BRCA1 mutations and sporadic tumors; six of the 53 mapped to Xp11.23 and were expressed at higher levels in tumors with BRCA1 mutations than in sporadic tumors. Compared with the immortalized ovarian surface epithelial cells used as reference, several interferon-inducible genes were overexpressed in the majority of tumors with a BRCA mutation and in sporadic tumors. CONCLUSIONS Mutations in BRCA1 and BRCA2 may lead to carcinogenesis through distinct molecular pathways that also appear to be involved in sporadic cancers. Sporadic carcinogenic pathways may result from epigenetic aberrations of BRCA1 and BRCA2 or their downstream effectors.
Collapse
MESH Headings
- Adenocarcinoma, Clear Cell/genetics
- Adenocarcinoma, Clear Cell/metabolism
- Adenocarcinoma, Mucinous/genetics
- Adenocarcinoma, Mucinous/metabolism
- Aged
- BRCA1 Protein/genetics
- BRCA2 Protein/genetics
- Carcinoma, Endometrioid/genetics
- Carcinoma, Endometrioid/metabolism
- Cystadenocarcinoma, Serous/genetics
- Cystadenocarcinoma, Serous/metabolism
- DNA Primers/chemistry
- Female
- Gene Expression Profiling
- Gene Expression Regulation, Neoplastic
- Genotype
- Germ-Line Mutation
- Humans
- Middle Aged
- Oligonucleotide Array Sequence Analysis
- Ovarian Neoplasms/genetics
- Ovarian Neoplasms/metabolism
- RNA, Messenger/analysis
- RNA, Messenger/genetics
- RNA, Neoplasm/analysis
- Reverse Transcriptase Polymerase Chain Reaction
Collapse
Affiliation(s)
- Amir A Jazaeri
- Division of Clinical Sciences of the National Cancer Institute, Gaithersburg, MD,USA
| | | | | | | | | | | |
Collapse
|
493
|
Abstract
The primary focus of this work was to determine the feasibility of obtaining representative expression array profiles from clinical core biopsies. For this purpose we performed six 16-gauge needle core biopsies and an excision biopsy on each of two different human xenografts, one from an Ewing's sarcoma cell line and the second from neuroblastoma cell line grown in Beige-Scid mice. Three of the six core biopsies were processed separately and the remaining three were pooled and processed together. As the initial RNA material isolated from the core biopsies was not sufficient for microarray analysis, an amplification procedure using a modified Eberwine protocol was performed, and the amplified products applied onto a 6000-feature human cDNA microarray. Comparisons of the array results from core biopsies (amplified RNA) and surgical specimens (non-amplified RNA) showed maintenance of the expression profile as assessed by hierarchical clustering. Gene expression profiles obtained from microarray analysis clearly differentiated the Ewing's sarcoma from the neuroblastoma with both core and excisional biopsies as starting material. Pooling the core biopsies did not improve the concordance with excisional biopsies. In conclusion, our results suggest that core biopsies can be used as a suitable and reliable material for the determination of tumor genetic profiles.
Collapse
Affiliation(s)
- Christos Sotiriou
- Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Gaithersburg, Maryland, USA
| | | | | | | | | |
Collapse
|
494
|
Abstract
Recent reports detailing the expression profiles of primary breast cancer have pointed to the utility of this approach in defining subclasses with distinct molecular configurations and clinical behaviour. Some of the subclasses can be predicted by current molecular tests: estrogen receptor status, p53 staining, and HER-2 overexpression. Others, however, are novel subgroups and may represent distinct cellular types. The results from two recent studies suggest common principles of classification by expression profiling. These principles are examined and the impact of these results on understanding the biology and the clinical behaviour of breast tumors is explored.
Collapse
Affiliation(s)
- Edison T Liu
- Genome Institute of Singapore, 1 Science Park Road, #05-01 Science Park II, Singapore.
| | | |
Collapse
|
495
|
Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, Gadisetti C, Libutti SK, Liu ET. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 2002; 4:R3. [PMID: 12052255 PMCID: PMC111028 DOI: 10.1186/bcr433] [Citation(s) in RCA: 158] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2001] [Revised: 02/12/2002] [Accepted: 03/04/2002] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND Drug resistance in breast cancer is a major obstacle to successful chemotherapy. In this study we used cDNA microarray technology to examine gene expression profiles obtained from fine needle aspiration (FNA) of primary breast tumors before and after systemic chemotherapy. Our goal was to determine the feasibility of obtaining representative expression array profiles from limited amounts of tissue and to identify those expression profiles that correlate with treatment response. METHODS Repeat presurgical FNA samples were taken from six patients who were to undergo primary surgical treatment. Additionally, a group of 10 patients who were to receive neoadjuvant chemotherapy underwent two FNAs before chemotherapy (adriamycin 60 mg/m2 and cyclophosphamide 600 mg/m2) followed by another FNA on day 21 after the first cycle. Total RNA was amplified with T7 Eberwine's procedure and labeled cDNA was hybridized onto a 7600-feature glass cDNA microarray. RESULTS We identified candidate gene expression profiles that might distinguish tumors with complete response to chemotherapy from tumors that do not respond, and found that the number of genes that change after one cycle of chemotherapy was 10 times greater in the responding group than in the non-responding group. CONCLUSION This study supports the suitability of FNA-derived cDNA microarray expression profiling of breast cancers as a comprehensive genomic approach for studying the mechanisms of drug resistance. Our findings also demonstrate the potential of monitoring post-chemotherapy changes in expression profiles as a measure of pharmacodynamic effect and suggests that these approaches might yield useful results when validated by larger studies.
Collapse
Affiliation(s)
- Christos Sotiriou
- Division of Clinical Sciences, Advanced Technology Center, National Cancer Institute, National Institutes of Health, Gaithersburg, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
496
|
Sotiriou C, Lacroix M, Lespagnard L, Larsimont D, Paesmans M, Body JJ. Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. Cancer Lett 2001; 169:87-95. [PMID: 11410329 DOI: 10.1016/s0304-3835(01)00524-9] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Breast cancers frequently metastasize to bone where they often cause extensive tumor-induced osteoclast-mediated osteolysis. Interleukin-6 (IL-6) and IL-11 are two cytokines exhibiting osteolytic properties through their potent stimulation of osteoclast formation. We investigated the expression of IL-6 and IL-11 in 99 invasive primary breast tumors by immunohistochemistry and in situ hybridization, respectively. We examined their potential as predictive factors for further development of bone metastases. 52/90 (57%) of tumor samples showed IL-6 cytoplasmic immunostaining. There was no significant association between IL-6 status and any of the classical prognostic factors. 15/89 (17%) of the tumor samples expressed IL-11 mRNA. A positive IL-11 mRNA status was associated with a low tumor grade (P=0.05). Tumors expressing IL-11 mRNA had a statistically significant (P=0.002) higher rate of bone metastases occurrence (12/15, 80%) than IL-11 negative tumors (27/74, 37%). Such association was not found for IL-6. Our findings demonstrate for the first time IL-11 gene expression in some primary invasive breast tumors and suggest the potential of this cytokine as possible biological predictive factor for the development of bone metastases.
Collapse
Affiliation(s)
- C Sotiriou
- Laboratory of Endocrinology/Bone Metabolism and Breast Cancer Research, Institut Jules Bordet, Boulevard de Waterloo, 127B-1000, Brussels, Belgium
| | | | | | | | | | | |
Collapse
|
497
|
Sotiriou C, Chand K, Petersen D, Jazaeri AA, Liu ET. Core biopsy versus surgical tumor specimens for microarray analysis of gene expression profiles. Nat Genet 2001. [DOI: 10.1038/87312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
498
|
Jazaeri A, Lu K, Sotiriou C, Alkharouf N, Gershenson D, Liu E. Gene expression profiles of low- and high-grade papillary serous ovarian carcinomas using cDNA microarray analysis. Nat Genet 2001. [DOI: 10.1038/87136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
499
|
Sotiriou C, Lacroix M, Lagneaux L, Berchem G, Body JJ. The aspirin metabolite salicylate inhibits breast cancer cells growth and their synthesis of the osteolytic cytokines interleukins-6 and -11. Anticancer Res 1999; 19:2997-3006. [PMID: 10652584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
Some epidemiological studies have suggested that aspirin could be a chemopreventive agent against breast cancer. We tested the effects of the aspirin metabolite salicylate (SA) on four (Hs578T, MCF-7, MDA-MB-231, and T-47D) breast cancer cell (BCC) lines in vitro. Two features were studied: the proliferation of BCC and their production of the osteolytic cytokines interleukins-6 (IL-6) and -11 (IL-11) since BCC frequently metastasize to bone and induce tumor-induced osteolysis. SA, from 0.5 to 5 mM, caused BCC growth inhibition by up to 70% (IC50 range 2.54 to 4.28 mM). At high concentrations, the drug induced apoptosis only (MDA-MB-231), or both apoptosis and primary necrosis (MCF-7). SA, as well as indomethacin (INDO), reduced the synthesis of IL-6 and -11, at both the protein and mRNA levels, in the two cell lines producing these cytokines (MDA-MB-231 and Hs578T). This latter effect seemed to be mediated by PGE2 since SA and INDO reduced PGE2 levels in MDA-MB-231 and Hs578T cells, PGE2 was not detected in MCF-7 and T-47D cells and exogenous PGE2 increased IL-6 and -11 expression by MDA-MB-231 cells. Collectively, our results suggest that SA could reduce the growth of breast tumors and inhibit to some extent the ability of BCC to induce osteoclast recruitment and osteolysis. These data indicate the need for further epidemiological and experimental studies.
Collapse
Affiliation(s)
- C Sotiriou
- Laboratory of Endocrinology, Bone Metabolism and Breast Cancer Research, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | | | | | | | | |
Collapse
|
500
|
Luce S, Paesmans M, Berghmans T, Castaigne C, Sotiriou C, Vermylen P, Sculier JP. [Critical review of the randomized trials assessing the role of adjuvant thoracic irradiation and chemotherapy in the treatment of limited-stage small cell lung cancer]. Rev Mal Respir 1998; 15:633-41. [PMID: 9834991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
The role of chest irradiation in the treatment of small cell lung cancer remains controversial. Two meta-analyses have shown a significant improvement of survival when this therapy is associated to chemotherapy but the controlled studies individually lead to contradictory conclusions. We have performed qualitative and quantitative evaluation of the literature on this topic in order to try to clarify this problem. On 15 published trials, 8 only give sufficient data allowing a meta-analysis. This does not show that chest irradiation improves statistically significantly survival in comparison to chemotherapy alone (odds ratio = 0.82; 95% CI: 0.63-1.07). The qualitative evaluation has been performed with the Chalmers and ELCWP scales. The scores obtained by both methods are highly correlated. There is no significant difference between the scores obtained by studies showing a survival improvement with irradiation or by negative studies. Very few trials report important criteria like definition of the primary end-point or the a priori estimate of the population size, attesting important methodological deficiencies. In conclusion, the quantitative aggregation of studies seems difficult to interpret because of the non optimal quality of the studies.
Collapse
Affiliation(s)
- S Luce
- Service de Médecine Interne, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgique
| | | | | | | | | | | | | |
Collapse
|